Radioligand therapy (RLT) has emerged as a transformative advancement in precision cancer treatment, offering improved outcomes for patients with advanced cancers. However, despite growing clinical evidence demonstrating favorable benefit-risk profiles, outdated regulatory frameworks continue to restrict patient access. This article addresses this critical issue. Through a comprehensive analysis of regulatory frameworks, clinical guidelines, and real-world implementation data across multiple healthcare systems, the authors identify systemic policy gaps and implementation challenges that hinder the widespread adoption of RLT. The article provides actionable recommendations to enable healthcare systems to optimize RLT delivery while maintaining safety standards, aiming to bridge the gap between scientific evidence and policy implementation.
Link to article: https://juniperpublishers.com/jojph/JOJPH.MS.ID.555786.php